NovaBay Pharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    549300D5U7PQPNEX8Q38
    ISIN
    US66987P4090 (NBY)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    47 / 100
    Worse than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. Read full profile

    Fundamentals

    Net revenue
    €4.05M
    Gross margin
    64.4%
    EBIT
    -€6.42M
    EBIT margin
    -158.5%
    Net income
    €2.84M
    Net margin
    70.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €13.48M +232.6% -€2.18M -177.0%
    N/A N/A
    N/A N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.80
    Ex date

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Earnings Calls

    Latest earnings call: May 9, 2024 (Q1 2024)

    Add to watchlist

    Notifications